Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

HAEMONETICS CORP Director's Dealing 2014

Mar 7, 2014

31565_dirs_2014-03-07_4acf7949-ab64-4b73-8f81-84b1dd86d2b5.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2014-03-06

Reporting Person: GELBMAN RONALD G (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2014-03-06 Common Stock M 12000.0 $13.0525 Acquired 51173 Direct
2014-03-06 Common Stock S 12000.0 $36.1679 Disposed 39173 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2014-03-06 Non-Qualified Stock Option (right to buy) $13.0525 M 12000.0 Disposed 2014-05-05 Common Stock (12000) Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Non-Qualified Stock Option (right to buy) $24.96 2014-08-01 Common Stock (9184) 9184 Direct
Non-Qualified Stock Option (right to buy) $27.24 2017-07-29 Common Stock (8580) 8580 Direct
Non-Qualified Stock Option (right to buy) $29.23 2015-07-31 Common Stock (11328) 11328 Direct
Non-Qualified Stock Option (right to buy) $29.72 2016-07-30 Common Stock (11758) 11758 Direct
Non-Qualified Stock Option (right to buy) $34.405 2018-07-21 Common Stock (7118) 7118 Direct
Non-Qualified Stock Option (right to buy) $36.37 2019-07-27 Common Stock (8196) 8196 Direct
Non-Qualified Stock Option (right to buy) $45.45 2023-07-24 Common Stock (6573) 6573 Direct

Footnotes

F1: Grant to reporting person of right to buy shares of common stock exercisable immediately.

F2: Grant to reporting person of right to buy shares of common stock exercisable 100 percent on the first anniversary of the date of grant.